⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Nucleix and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Nucleix
↗Rehovot, Israel
Nucleix is a liquid biopsy company focused on revolutionizing cancer treatment through early disease detection and recurrence monitoring. The company leverages proprietary, ultra-sensitive methylation-based epigenetics technology, known as EpiCheck®, which is compatible with both next-generation sequencing (NGS) and polymerase chain reaction (PCR) platforms.
Nucleix operates with a global footprint, maintaining headquarters in Rehovot, Israel, and a significant operational presence in San Diego, USA. The company's platform is designed to detect minute cancer-specific epigenetic signals from blood or urine samples, aiming to provide highly accurate, non-invasive diagnostic solutions for patients and healthcare systems.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2008
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$88.5M
Investors:RA Capital Management, BlackRock, Lilly Asia Ventures, OrbiMed, Sands Capital, LYFE Capital, Aurum Ventures, DSC Investment, OCI Bio Investments, Zohar Zisapel
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Bladder EpiCheck)
Modalities:Molecular Diagnostics, Liquid Biopsy
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Collaborations with various medical centers and laboratories across Europe and North America for clinical validation studies.
COMPETITION
Position:Challenger
Competitors:Guardant Health, Delfi Diagnostics, BillionToOne, Biodesix, GRAIL
LEADERSHIP
Key Executives:
Chris Hibberd - CEO
Todd Myers - CFO
Catherine Schnabel - Chief Scientific Officer
Scientific Founders:Adam Wasserstrom, Danny Frumkin, Elon Ganor
LINKS
Website:nucleix.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Nucleix. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.